Deal-Making

Big Pharma collaborative trend to continue beyond COVID

Manufacturing collaboration between traditional rivals will be normal post-pandemic say GSK and Merck & Co., both of which are using their capacity to support fellow Big Pharma COVID-19 efforts. The biopharma space has traditionally been a highly competitive arena. Retaining intellectual property through secrecy, litigation, and other means is crucial to ensure maximum revenues from products developed at high-cost and high-risk. Just look at how the entrance of biosimilars have decimated certain company’s top line results. But a new era…

Ins & outs: CureVac names new chief development officer

CureVac has named Klaus Edvardsen as its chief development officer. Meanwhile, there are changes at Gamida Cell and AavantiBio. Sit back, relax, and enjoy BioProcess Insider’s Ins & outs. Up first in this week’s Ins & Out’s we have mRNA firm CureVac, which has appointed Edvardsen as chief development officer effective from August 1, 2021. “We are very pleased that Klaus is joining us in highly dynamic times for the company,” said Franz-Werner Haas, CEO of CureVac. “He brings a wealth of…

Industry consortium takes aim at lowering CGT production costs

GSK, Cytiva, and Lonza are among 20 companies looking to develop technologies aimed at lowering the cost of cell and gene therapy production. Over 20 companies have been brought together by the Cell and Gene Therapy Catapult (CGT Catapult) to assess multiple process analytical technologies (PAT), which are new or frequently used in other sectors. This is the first consortium of this scale with the 20 companies consisting of technology providers, therapy developers, charities, and pharmaceutical firms. The consortium has…

Resilience to support AavantiBio’s gene therapy programs long-term

AavantiBio has hired Resilience to make its gene therapies candidates, including a therapy for the currently untreatable progressive disorder Friedreich’s Ataxia (FA). Under the contract – described as a strategic collaboration – Resilience will provide process development and manufacturing as well as including cell lines and viral banks for in pre-clinical studies and clinical trials. The contract development and manufacturing organization (CDMO) will also develop and optimize processes for AvantBio’s other candidate therapies, with all of the work scheduled to…

Dyadic: For COVID-19 vaccines, ‘we have what the world needs’

The industry needs to rethink COVID-19 vaccine production according to Dyadic, which says its fungus-based expression system could supply the world at a lower cost than current mRNA offerings. As the global COVID-19 vaccine rollout continues and companies like Moderna and Pfizer become household names, Dyadic CEO Mark Emalfarb told BioProcess Insider its C-1 cell protein production platform could potentially produce “antigens, quicker, faster, and in larger volumes at a lower cost.” He continued: “We could have seeded the world…

Avantor boosts single-use production with RIM buy

Avantor has added a manufacturing plant in Changzhou, China through the acquisition of single-use bag and system producer RIM Bio. The acquisition – financials of which have not been divulged – brings Avantor a facility in China that produces single-use systems including 2D bags, 3D bags, tank liners, bag assemblies and multi-bag manifolds used in the manufacturing of biologics, vaccines, and advanced therapies. Avantor said the addition of its first Asian single-use facility will help boost its global capabilities and capacity…

Ins & outs: Apeiron Biologics expands management board

Apeiron Biologics makes high level changes to management and supervisory board. Meanwhile, there are changes at Relief Therapeutics. Sit back, put your feet up, and enjoy BioProcess Insider’s Ins & outs. Up first in this week’s Ins & Outs is Apeiron Biologics, a biotech firm that develops immunotherapies for respiratory diseases and cancer. According to the company, it is expanding its management board and supervisory board to meet the firm’s growth requirements. Romana Gugenberger has been appointed as chief medical and…

Danaher boosts lipid services through PNI acquisition

Danaher will increase its lipid service offerings through the acquisition of Canadian-based technology and solution firm Precision Nanosystems. The deal, of which financials have not been disclosed, sees lipid nanoparticle tech firm Precision Nanosystems (PNI) join Danaher Corporation’s family of life science companies, which include Cytiva and Pall. PNI offers consumables, equipment, and reagents to help manufacture lipid nanoparticles for the delivery of genetic medicines, including messenger RNA (mRNA) therapeutics and vaccines. Through the acquisition, Danaher gains PNI’s GenVoy delivery…

Swiss gov helps Lonza recruit staff to manufacture Moderna vaccine

The Swiss government has recruited at least 25 workers to operate the production lines at Lonza’s facility in Visp. Contract development manufacturing organization (CDMO) Lonza has been supporting Moderna since May 2020 to manufacture its cell-free messenger RNA (mRNA) COVID-19 vaccine. However, there have been concerns regarding supply delays and it was even alleged the CDMO had tapped fellow Swiss company Nestle for workers in order to service its deal to produce drug substance for hundreds of millions of doses of Moderna’s…

Avid secures commercial manufacturing contract for ADC’s Zynlonta

ADC Therapeutics’ recently approved cancer treatment Zynlonta will be commercially manufactured by Avid Bioservices in Tustin, California.   Contract development manufacturing organization (CDMO) Avid Bioservices will manufacture the monoclonal antibody portion of the antibody-drug conjugate (ADC) Zynlonta (loncastuximab tesirine), which received US Food and Drug Administration (FDA) approval in April. Avid has provided ADC Therapeutics with clinical manufacturing services since 2017. However, the firm will now undertake commercial manufacturing activities for Zynlonta, which is used to treat patients with relapsed or…